| __timestamp | Lantheus Holdings, Inc. | Supernus Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 176081000 | 5758000 |
| Thursday, January 1, 2015 | 157939000 | 8423000 |
| Friday, January 1, 2016 | 164073000 | 11986000 |
| Sunday, January 1, 2017 | 169243000 | 15215000 |
| Monday, January 1, 2018 | 168489000 | 15356000 |
| Tuesday, January 1, 2019 | 172526000 | 16660000 |
| Wednesday, January 1, 2020 | 200649000 | 52459000 |
| Friday, January 1, 2021 | 237513000 | 75061000 |
| Saturday, January 1, 2022 | 353358000 | 87221000 |
| Sunday, January 1, 2023 | 586886000 | 83779000 |
In pursuit of knowledge
In the ever-evolving landscape of the pharmaceutical industry, understanding cost structures is pivotal. Lantheus Holdings, Inc. and Supernus Pharmaceuticals, Inc. offer a fascinating glimpse into this dynamic. Over the past decade, Lantheus Holdings has seen its cost of revenue surge by over 230%, peaking at approximately $587 million in 2023. This growth reflects the company's strategic investments and expanding market presence.
Conversely, Supernus Pharmaceuticals has maintained a more modest trajectory, with its cost of revenue increasing by around 1,350% since 2014, reaching nearly $84 million in 2023. This steady rise underscores the company's focus on sustainable growth and efficient resource allocation.
These insights highlight the contrasting strategies of two industry players, offering valuable lessons in cost management and growth optimization. As the pharmaceutical sector continues to innovate, understanding these cost dynamics will be crucial for stakeholders and investors alike.
Novo Nordisk A/S vs Lantheus Holdings, Inc.: Efficiency in Cost of Revenue Explored
Analyzing Cost of Revenue: Teva Pharmaceutical Industries Limited and Supernus Pharmaceuticals, Inc.
Cost Insights: Breaking Down Walgreens Boots Alliance, Inc. and Supernus Pharmaceuticals, Inc.'s Expenses
Cost Insights: Breaking Down Pharming Group N.V. and Supernus Pharmaceuticals, Inc.'s Expenses
Cost of Revenue Comparison: Lantheus Holdings, Inc. vs MorphoSys AG
Analyzing Cost of Revenue: Lantheus Holdings, Inc. and Amphastar Pharmaceuticals, Inc.
Cost of Revenue Trends: Lantheus Holdings, Inc. vs Taro Pharmaceutical Industries Ltd.
Lantheus Holdings, Inc. vs MiMedx Group, Inc.: Efficiency in Cost of Revenue Explored
Corcept Therapeutics Incorporated vs Supernus Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Analyzing Cost of Revenue: Cytokinetics, Incorporated and Supernus Pharmaceuticals, Inc.
Comparing Cost of Revenue Efficiency: Supernus Pharmaceuticals, Inc. vs Wave Life Sciences Ltd.
Comparing Cost of Revenue Efficiency: Supernus Pharmaceuticals, Inc. vs Taro Pharmaceutical Industries Ltd.